|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15051506150715081509151015111512151315141515...15771578» |
- | Journal: A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. (Pubmed Central) - Apr 16, 2017
MBC is associated with a poor prognosis, despite low nodal involvement. Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy.
- | Trial completion: The Oncopanel Pilot (TOP) Study (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=432, Completed, Sponsor: British Columbia Cancer Agency
Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy. Active, not recruiting --> Completed
- || emactuzumab (RG7155) / SynOx Therap, Tecentriq (atezolizumab) / Roche
Enrollment change, Metastases: A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 14, 2017
P1, N=310, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=162 --> 310
- | Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Enrollment closed, Combination therapy, Stroma, Metastases: BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Apr 14, 2017
P1/2, N=62, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=162 --> 310 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Biomarker, New trial: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=165, Not yet recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
- | Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) (clinicaltrials.gov) - Apr 13, 2017
P2, N=48, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- | Trial primary completion date: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Apr 13, 2017
P2, N=100, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Aug 2018
- | Trial primary completion date, MRI: Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection (clinicaltrials.gov) - Apr 12, 2017
P=N/A, N=16, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Aug 2016 --> Aug 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- | Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Surgery, Metastases: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 12, 2017
P1b, N=36, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- | Koselugo (selumetinib) / Merck (MSD), AstraZeneca
New P2 trial, Stroma: Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Apr 12, 2017
P2, N=20, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | doxorubicin hydrochloride / Generic mfg.
New P1 trial: Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children (clinicaltrials.gov) - Apr 12, 2017
P1, N=28, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Journal: Early Results of Acetabular Reconstruction After Wide Periacetabular Oncologic Resection. (Pubmed Central) - Apr 12, 2017
As expected due to the lack of a functioning abductor mechanism from the wide oncologic resection, early dislocations remain a concern. As such, we now consider the primary use of increasing constraint, but it must be balanced with the often compromised host bone.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
Trial initiation date, Surgery: RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Apr 11, 2017
P2, N=100, Recruiting, Sponsor: St. Jude Children's Research Hospital
As such, we now consider the primary use of increasing constraint, but it must be balanced with the often compromised host bone. Initiation date: Jun 2013 --> Dec 2013
- | Phase classification: Methionine PET/CT Studies In Patients With Cancer (clinicaltrials.gov) - Apr 11, 2017
P2, N=650, Recruiting, Sponsor: St. Jude Children's Research Hospital
Initiation date: Jun 2013 --> Dec 2013 Phase classification: P=N/A --> P2
- |||| trivalent ganglioside vaccine / MabVax
Trial completion, Metastases: Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free (clinicaltrials.gov) - Apr 11, 2017
P2, N=136, Completed, Sponsor: MabVax Therapeutics, Inc.
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment open, Trial initiation date: Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov) - Apr 11, 2017
P2, N=36, Recruiting, Sponsor: AIDS Malignancy Consortium
Active, not recruiting --> Completed Suspended --> Recruiting | Initiation date: Sep 2016 --> Mar 2017
- | Enrollment open, Surgery: Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=160, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Suspended --> Recruiting | Initiation date: Sep 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- | Biomarker, New trial, IO biomarker: Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=40, Not yet recruiting, Sponsor: Ruijin Hospital
- | propranolol / Generic mfg.
New P2 trial, Metastases: Use of Propranolol Hydrochloride in the Treatment of Metastatic STS (clinicaltrials.gov) - Apr 10, 2017
P2, N=50, Not yet recruiting, Sponsor: Ain Shams University
- | navtemadlin (KRT-232) / Kartos Therap
New P1 trial, Combination therapy: ALLIANCE-ABTC-1604: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (clinicaltrials.gov) - Apr 10, 2017
P1, N=92, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | New trial: MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=30, Not yet recruiting, Sponsor: Turku University Hospital
- | Journal: Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma. (Pubmed Central) - Apr 9, 2017
Importantly, we showed that the phosphorylation of Akt was correlated with CAM-DR phenotype in NHL cells. Taken together, the present study shed new light on the molecular mechanism of CAM-DR in NHL and targeting CKIP-1 may be a novel therapeutic target for NHL.
- docetaxel nanoliposome (MM-310) / Merrimack
Enrollment open: A Study Evaluating MM-310 in Patients With Solid Tumors (clinicaltrials.gov) - Apr 8, 2017
P1, N=34, Recruiting, Sponsor: Merrimack Pharmaceuticals
Taken together, the present study shed new light on the molecular mechanism of CAM-DR in NHL and targeting CKIP-1 may be a novel therapeutic target for NHL. Not yet recruiting --> Recruiting
- | Journal: Management and follow-up of Ewing sarcoma patients with isolated lung metastases. (Pubmed Central) - Apr 8, 2017
Metastatectomy may have a role in the treatment of highly selected patients with ES and isolated lung metastases depending on the histologic response to therapy. Further studies are needed to better define the use of surgery and the response-adapted criteria in the upfront management of this population.
- | Journal: Multimodality Imaging Approach towards Primary Aortic Sarcomas Arising after Endovascular Abdominal Aortic Aneurysm Repair: Case Series Report. (Pubmed Central) - Apr 8, 2017
Radiologists are rarely knowledgeable about this rare entity for which multimodality imaging and awareness are invaluable in early diagnosis. A series of three pathologically confirmed cases are presented to display the multimodality imaging features and clinical presentations of aortic sarcoma arising after EVAR.
- | Journal: Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene. (Pubmed Central) - Apr 8, 2017
In contrast, no aneuploidy was found for 10 macrochromosomes of 12 spreads of normal chicken embryo fibroblast cells, although aneuploidy for some microchromosomes was demonstrated in five of the 12 spreads. The cytogenetic mosaicism or polymorphism of the aneuploidy in the acute fibrosarcoma described in this study suggests that the analysed cells are polyclonal.
- | Journal: RUNX2 controls human IPO8 basal transcription in Saos-2 cells. (Pubmed Central) - Apr 8, 2017
Finally, synchronization of IPO8 and RUNX2 expression was observed in Saos‑2 cells cultured in osteoblast‑induction medium. Taken together, these results indicated that RUNX2 regulates IPO8 gene transcription, and may have a contributory role in osteoblast differentiation.
- | Journal: Biatrial High-Grade Leiomyosarcoma With Nine-Year Post-Surgical Survival. (Pubmed Central) - Apr 8, 2017
We present a 53-year-old female patient with biatrial leiomyosarcoma with inferior vena cava and coronary sinus involvement who underwent aggressive surgical resection with reconstruction of her left and right atrium and coronary sinus with bovine pericardium followed by adjuvant radiation therapy. She is living well with no recurrence 9 years after diagnosis.
- sirolimus / Generic mfg.
Trial primary completion date: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=15, Recruiting, Sponsor: Maine Medical Center
She is living well with no recurrence 9 years after diagnosis. Trial primary completion date: Mar 2017 --> Mar 2019
- | SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
Trial primary completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=50, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Mar 2017 --> Mar 2019 Trial primary completion date: Apr 2017 --> Apr 2018
- | Danyelza (naxitamab) - Y / mAbs Therap
Enrollment change, Trial primary completion date: PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=15, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 N=30 --> 15 | Trial primary completion date: Nov 2017 --> Nov 2018
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, New trial, Metastases: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=0, Approved for marketing, Sponsor: Peking University People's Hospital
- | Halaven (eribulin mesylate) / Eisai
Review, Journal: Eribulin in non-small cell lung cancer: challenges and potential strategies. (Pubmed Central) - Apr 6, 2017
However, the management of NSCLC is undergoing rapid evolution with introduction of newer immune mediated and targeted agents. The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (clinicaltrials.gov) - Apr 6, 2017
P2, N=60, Not yet recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
The way to move forward is to combine eribulin with novel immune checkpoint inhibitors, targeted agents and chemotherapies in appropriate line of therapy. Initiation date: Dec 2016 --> Jun 2017 | Trial primary completion date: Feb 2023 --> Aug 2023
- | Enrollment open: A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) (clinicaltrials.gov) - Apr 6, 2017
P=N/A, N=25, Recruiting, Sponsor: The Netherlands Cancer Institute
Initiation date: Dec 2016 --> Jun 2017 | Trial primary completion date: Feb 2023 --> Aug 2023 Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
Enrollment open, Enrollment change, Trial primary completion date: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Apr 5, 2017
P1, N=55, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
Not yet recruiting --> Recruiting Suspended --> Recruiting | N=40 --> 55 | Trial primary completion date: Jan 2017 --> Dec 2018
- ||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Enrollment change, Trial primary completion date: A Study of R1507 in Participants With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 4, 2017
P2, N=317, Completed, Sponsor: Hoffmann-La Roche
Suspended --> Recruiting | N=40 --> 55 | Trial primary completion date: Jan 2017 --> Dec 2018 N=228 --> 317 | Trial primary completion date: Jun 2010 --> Feb 2014
- | Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma (clinicaltrials.gov) - Apr 4, 2017
P2, N=30, Recruiting, Sponsor: Assaf-Harofeh Medical Center
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion, P1 data: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Apr 4, 2017
P1, N=54, Completed, Sponsor: Karyopharm Therapeutics Inc
N=228 --> 317 | Trial primary completion date: Jun 2010 --> Feb 2014 Active, not recruiting --> Completed
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial primary completion date, HEOR: YonLife: Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=77, Recruiting, Sponsor: GWT-TUD GmbH
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> May 2017
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=19, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Apr 2017 --> Apr 2018
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Trial initiation date, Combination therapy: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (clinicaltrials.gov) - Apr 4, 2017
P1, N=54, Not yet recruiting, Sponsor: David Wald
Trial primary completion date: Apr 2017 --> Apr 2018 N=27 --> 54 | Initiation date: Oct 2016 --> May 2017
- | New trial: EPISObs: An Observational Study on Epithelioid Sarcoma (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Italian Sarcoma Group
- | Journal: LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma. (Pubmed Central) - Apr 2, 2017
N=27 --> 54 | Initiation date: Oct 2016 --> May 2017 Our data provided evidence that TUG1 was upregulated and acted as a possible oncogene via positively regulating cell proliferation in osteosarcoma cells.
- | Journal: Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review. (Pubmed Central) - Apr 2, 2017
Our data provided evidence that TUG1 was upregulated and acted as a possible oncogene via positively regulating cell proliferation in osteosarcoma cells. No abstract available
- | Journal: Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. (Pubmed Central) - Apr 2, 2017
Acceptable dose constraints for RPS may be higher than those for GI or GYN cancers. Further assessment of dose-volume constraints for RPS is needed.
- | Journal: Minimally invasive rib-sparing video-assisted thoracoscopic surgery resections with high-dose-rate intraoperative brachytherapy for selected chest wall tumors. (Pubmed Central) - Apr 2, 2017
Short-term morbidity associated with chest wall resection may be reduced. Additional study is required to define long-term benefits.
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov) - Mar 31, 2017
P2, N=26, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Additional study is required to define long-term benefits. Not yet recruiting --> Recruiting
- | imatinib / Generic mfg.
Enrollment change, Trial termination, Stroma: ABILITY: Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (clinicaltrials.gov) - Mar 31, 2017
P1, N=5, Terminated, Sponsor: Radboud University
Not yet recruiting --> Recruiting N=12 --> 5 | Recruiting --> Terminated; inclusion was too slow
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Mar 30, 2017
P2, N=30, Completed, Sponsor: Center for Neurosciences, Tucson
N=12 --> 5 | Recruiting --> Terminated; inclusion was too slow Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2014